BACKGROUND/OBJECTIVES: The association between nutritional status and health-related quality of life (HRQoL) among patients with type 2 diabetes mellitus (T2DM) is not fully understood. This study was conducted to understand the role of nutritional status on HRQoL among people with and without T2DM. SUBJECTS/METHODS: Structured survey and direct measurement of anthropometric data were conducted among people with and without T2DM. Nutritional status was measured with Mini Nutritional Assessment tool and HRQoL was measured with a 36-item Short Form Healthy Survey. Data collection was conducted in Chuncheon, South Korea with 756 participants who are older than 40 yrs of age. RESULTS: This study found that overall HRQoL were significantly lower in people with T2DM than people without T2DM after controlling for key covariates. When stratified by nutritional status, a greater degree of negative impact of T2DM on overall physical HRQoL was observed among well-nourished or at risk of malnutrition, whereas significant and more evident negative impact of diabetes on overall psychological HRQoL was observed only among malnourished. CONCLUSIONS The study results suggest the role of nutritional status among people with T2DM on overall, especially psychological aspects of HRQoL. Future longitudinal or intervention studies are warranted to test the impact of nutritional status on HRQoL among people with T2DM.

Background: Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive to conventional therapy and display high disease severity, which calls for further research. We aimed to determine survival, prognosis, and clinical feature of patients with rMG compared to non-rMG. Methods: Retrospective nationwide cohort study using Korea's healthcare database between 2002 and 2017 was conducted. Patients with rMG (n = 47) and non-rMG (n = 4,251) who were aged > 18 years, followed-up for ≥ 1 year, and prescribed immunosuppressants within 2 years after incident MG diagnosis were included. Patients with rMG were defined as administered plasma exchange or intravenous immunoglobulin at least 3 times per year after receiving ≥ 2 immunosuppressants. All-cause mortality, myasthenic crisis, hospitalization, pneumonia/ sepsis, and emergency department (ED) visits were measured using Cox proportional hazard models and pharmacotherapy patterns for rMG were assessed. Results: The rMG cohort included a preponderance of younger patients and women. The adjusted hazard ratio was 2.49 (95% confidence interval, 1.26–4.94) for mortality, 3.14 (2.25–4.38) for myasthenic crisis, 1.54 (1.15–2.06) for hospitalization, 2.69 (1.74–4.15) for pneumonia/sepsis, and 1.81 (1.28–2.56) for ED visits for rMG versus non-rMG. The immunosuppressant prescriptions were more prevalent in patients with rMG, while the difference was more remarkable before rMG onset rather than after rMG onset. Conclusion Despite the severe prognosis of rMG, the strategies for pharmacotherapeutic regimens were similar in those two groups, suggesting that intensive monitoring and introduction of timely treatment options in the early phase of MG are required.

Background: Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive to conventional therapy and display high disease severity, which calls for further research. We aimed to determine survival, prognosis, and clinical feature of patients with rMG compared to non-rMG. Methods: Retrospective nationwide cohort study using Korea's healthcare database between 2002 and 2017 was conducted. Patients with rMG (n = 47) and non-rMG (n = 4,251) who were aged > 18 years, followed-up for ≥ 1 year, and prescribed immunosuppressants within 2 years after incident MG diagnosis were included. Patients with rMG were defined as administered plasma exchange or intravenous immunoglobulin at least 3 times per year after receiving ≥ 2 immunosuppressants. All-cause mortality, myasthenic crisis, hospitalization, pneumonia/ sepsis, and emergency department (ED) visits were measured using Cox proportional hazard models and pharmacotherapy patterns for rMG were assessed. Results: The rMG cohort included a preponderance of younger patients and women. The adjusted hazard ratio was 2.49 (95% confidence interval, 1.26–4.94) for mortality, 3.14 (2.25–4.38) for myasthenic crisis, 1.54 (1.15–2.06) for hospitalization, 2.69 (1.74–4.15) for pneumonia/sepsis, and 1.81 (1.28–2.56) for ED visits for rMG versus non-rMG. The immunosuppressant prescriptions were more prevalent in patients with rMG, while the difference was more remarkable before rMG onset rather than after rMG onset. Conclusion Despite the severe prognosis of rMG, the strategies for pharmacotherapeutic regimens were similar in those two groups, suggesting that intensive monitoring and introduction of timely treatment options in the early phase of MG are required.

BACKGROUND: The accurate and early diagnosis of acute myeloid leukemia (AML) is important to choose proper treatment option depending on the risk stratification. The delta neutrophil index (DNI) is a relatively new blood marker that indicates the proportion of immature granulocytes in peripheral blood circulation. This study aimed to evaluate the diagnostic value of the DNI for detecting AML in the early phase of acute leukemia. METHODS: We retrospectively analyzed laboratory tests and bone marrow study results of 163 pediatric patients with acute leukemia admitted to the emergency department, who were diagnosed with acute leukemia. An automatic analyzer (ADVIA 2120 Hematology System; Siemens Healthcare Diagnostics, Forchheim, Germany) was used to measure the DNI in the peripheral blood of each patient. RESULTS: The mean DNI was significantly different between the AML (N=39) and non-AML (N=124) groups (P < 0.05), and the DNI was the only significant marker for predicting AML in patients with acute leukemia (odds ratio, 1.328; P < 0.05). The DNI more than 4.4% has the highest predictability for distinguishing the patients with AML from the patients with acute leukemia. The mean DNI of the acute promyelocytic leukemia (APL, N=8) group was statistically higher than that of the non-APL group (N=31, P=0.019), but the DNI was not significant in the univariate logistic regression analysis. CONCLUSION: The DNI might be a promising peripheral blood marker for predicting AML in the early work-up of patients with acute leukemia.
Blood Circulation ; Bone Marrow ; Child ; Delivery of Health Care ; Early Diagnosis ; Emergency Service, Hospital ; Granulocytes ; Hematology ; Humans ; Leukemia* ; Leukemia, Myeloid, Acute ; Leukemia, Promyelocytic, Acute ; Logistic Models ; Neutrophils* ; Retrospective Studies

Purpose: This study investigated the use of synthetic computed tomography (CT) images derived from cone beam CT (CBCT) scans to analyze dose changes in breast cancer patients undergoing treatment and to evaluate the optimal timing for implementing adaptive radiotherapy. Methods: A retrospective analysis was conducted on five breast cancer patients treated with tomotherapy-based volumetric-modulated arc therapy at Yongin Severance Hospital. Each patient received 15 fractions, with doses of 320 centigray (cGy) to the high-dose planning target volume (PTV) and 267 cGy to the low-dose PTV. Planning CT images were acquired using the Aquilion scanner, andCBCT images were captured with the VersaHD linear accelerator’s on-board imager. These imageswere registered in RayStation using a hybrid deformable image registration method to generate synthetic CT images. Dose distributions were reanalyzed using the synthetic CT images, and dose-volume histogram parameters, including the dose to 95% of the volume (D95 ) and mean dose (Dmean ) for the PTV, as well as D95 , Dmean , the percentage of the volume receiving at least 5 Gy (V5 ) and 10 Gy (V10 )for organs-at-risk (OARs), were extracted using MATLAB to assess dose changes during treatment. Results: For the original plans, the mean D95 for PTV high across all patients was 287.13±31.32cGy, while for PTV low, it was 245.53±6.21 cGy. In contrast, the adaptive plans yielded a mean D95of 298.17±12.37 cGy for PTV High and 247.25±4.23 cGy for PTV low. The ART Plan may lead to increased dose exposure in certain structures, such as the spinal cord, while providing targeted improvements in reducing radiation exposure in specific OARs (e.g., contralateral breast and esophagus). Conclusions Synthetic CT images generated from CBCT scans provide a fast and efficient means of quantifying dose changes, supporting precise patient care through interfractional evaluation.Future studies will aim to apply this method to other organs and larger patient cohorts.

Purpose: This study investigated the use of synthetic computed tomography (CT) images derived from cone beam CT (CBCT) scans to analyze dose changes in breast cancer patients undergoing treatment and to evaluate the optimal timing for implementing adaptive radiotherapy. Methods: A retrospective analysis was conducted on five breast cancer patients treated with tomotherapy-based volumetric-modulated arc therapy at Yongin Severance Hospital. Each patient received 15 fractions, with doses of 320 centigray (cGy) to the high-dose planning target volume (PTV) and 267 cGy to the low-dose PTV. Planning CT images were acquired using the Aquilion scanner, andCBCT images were captured with the VersaHD linear accelerator’s on-board imager. These imageswere registered in RayStation using a hybrid deformable image registration method to generate synthetic CT images. Dose distributions were reanalyzed using the synthetic CT images, and dose-volume histogram parameters, including the dose to 95% of the volume (D95 ) and mean dose (Dmean ) for the PTV, as well as D95 , Dmean , the percentage of the volume receiving at least 5 Gy (V5 ) and 10 Gy (V10 )for organs-at-risk (OARs), were extracted using MATLAB to assess dose changes during treatment. Results: For the original plans, the mean D95 for PTV high across all patients was 287.13±31.32cGy, while for PTV low, it was 245.53±6.21 cGy. In contrast, the adaptive plans yielded a mean D95of 298.17±12.37 cGy for PTV High and 247.25±4.23 cGy for PTV low. The ART Plan may lead to increased dose exposure in certain structures, such as the spinal cord, while providing targeted improvements in reducing radiation exposure in specific OARs (e.g., contralateral breast and esophagus). Conclusions Synthetic CT images generated from CBCT scans provide a fast and efficient means of quantifying dose changes, supporting precise patient care through interfractional evaluation.Future studies will aim to apply this method to other organs and larger patient cohorts.

Purpose: This study investigated the use of synthetic computed tomography (CT) images derived from cone beam CT (CBCT) scans to analyze dose changes in breast cancer patients undergoing treatment and to evaluate the optimal timing for implementing adaptive radiotherapy. Methods: A retrospective analysis was conducted on five breast cancer patients treated with tomotherapy-based volumetric-modulated arc therapy at Yongin Severance Hospital. Each patient received 15 fractions, with doses of 320 centigray (cGy) to the high-dose planning target volume (PTV) and 267 cGy to the low-dose PTV. Planning CT images were acquired using the Aquilion scanner, andCBCT images were captured with the VersaHD linear accelerator’s on-board imager. These imageswere registered in RayStation using a hybrid deformable image registration method to generate synthetic CT images. Dose distributions were reanalyzed using the synthetic CT images, and dose-volume histogram parameters, including the dose to 95% of the volume (D95 ) and mean dose (Dmean ) for the PTV, as well as D95 , Dmean , the percentage of the volume receiving at least 5 Gy (V5 ) and 10 Gy (V10 )for organs-at-risk (OARs), were extracted using MATLAB to assess dose changes during treatment. Results: For the original plans, the mean D95 for PTV high across all patients was 287.13±31.32cGy, while for PTV low, it was 245.53±6.21 cGy. In contrast, the adaptive plans yielded a mean D95of 298.17±12.37 cGy for PTV High and 247.25±4.23 cGy for PTV low. The ART Plan may lead to increased dose exposure in certain structures, such as the spinal cord, while providing targeted improvements in reducing radiation exposure in specific OARs (e.g., contralateral breast and esophagus). Conclusions Synthetic CT images generated from CBCT scans provide a fast and efficient means of quantifying dose changes, supporting precise patient care through interfractional evaluation.Future studies will aim to apply this method to other organs and larger patient cohorts.